Clinical Trial Detail

NCT ID NCT03407144
Title Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Merck Sharp & Dohme Corp.

Hodgkin's lymphoma


COPDAC-28 + Pembrolizumab

ABVD (Bleomycin + Dacarbazine + Doxorubicin + Vinblastine) + Pembrolizumab

Age Groups: adult child

No variant requirements are available.